AntiCoagAF
DOAC use in non-valvular AF
$1.99
1.3for iPhone, iPad and more
Age Rating
AntiCoagAF Screenshots
About AntiCoagAF
This application is for medical practitioners who need to quickly review which anticoagulant (including the direct oral anticoagulants (DOACs)) to use to prevent stroke in patients with non-valvular atrial fibrillation (NVAF).
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
It contains relevant information about warfarin, apixaban, dabigatran, rivaroxaban and edoxaban.
Topics covered include: comparison of anticoagulants, patient information, when anticoagulation is required, risk-benefit issues, when warfarin is appropriate, how to choose the dose of a DOAC, starting or switching between anticoagulants, edoxban information, clinical monitoring, bleeding risks, use of antiplatelet agents in addition to oral anticoagulants, managing ischemic strokes on DOACs, reversing anticoagulation in the event of intracerebral haemorrhage, a Cookcroft-Gault creatinine clearance calculator and peri-operative management information.
Information contained within the application was edited by Dr Bruce Campbell. Coding was by CereScape (www.cerescape.com). It is our aim to keep this information current, and we welcome constructive comments and evidenced updated information. Any profit generated by this application will be used to fund stroke research.
Show More
What's New in the Latest Version 1.3
Last updated on Feb 2, 2022
Old Versions
Updated by Prof Bruce Campbell, University of Melbourne, for 2022 use. Added information about new DOAC reversal agents. Helpful for management of stroke, peri-operative care and other decisions involving DOAC use.
Show More
Version History
1.3
Feb 2, 2022
Updated by Prof Bruce Campbell, University of Melbourne, for 2022 use. Added information about new DOAC reversal agents. Helpful for management of stroke, peri-operative care and other decisions involving DOAC use.
1.2.0
Dec 6, 2020
Minor bug fixes only.
1.1.1
Jun 14, 2020
Updated for iOS 13 in SwiftUI.
1.0.7
Jan 21, 2020
Sharing is simpler and uses all available local options. Updated source code to Swift.
1.04
Dec 4, 2016
Updated information about DOACS (no longer called NOACS).
1.0.3
Jun 15, 2016
Updated NOAC information, bug fixes, supports various orientations. Added edoxaban, inhibitor notes, Cockcroft-Gault creatinine clearance calculator.
1.0.2
Jan 9, 2015
- Updated content including imminent inhibitor information and other recent changes in determining safety for thrombolysis.
1.0.1
Dec 17, 2013
- Updated content to include USA and Europe dosages, other indications and more detailed adjustment information
- Disclaimer text no longer editable (sorry!)
- Disclaimer text no longer editable (sorry!)
1.0
Nov 26, 2013
AntiCoagAF FAQ
Click here to learn how to download AntiCoagAF in restricted country or region.
Check the following list to see the minimum requirements of AntiCoagAF.
iPhone
Requires iOS 15.0 or later.
iPad
Requires iPadOS 15.0 or later.
iPod touch
Requires iOS 15.0 or later.
AntiCoagAF supports English